Biotechnology company Biocon announced Q1FY26 results Operating Revenue for Q1FY26 grew 15% YoY to Rs 3,942 crore. Core EBITDA at Rs 1,003 crore, grew 11% with core operating margins of 25%. Net R&D; investments for the quarter were Rs 205 crore, representing 7% of revenue exSyngene. EBITDA for the quarter at Rs 829 crore, grew by 19 % with an EBITDA margin of 21% on a like for like basis. Profit Before Tax before exceptional items stood at Rs 97 crore, an increase of 72% on a like for like basis. Net Profitfor the quarter, before exceptional items, stood at Rs 31 crore with a growth of 342% on a like for like basis. Reported Net Profit for the quarter stood at Rs 31 crore, up 65% on a like for like basis. Kiran Mazumdar-Shaw, Chairperson, Biocon Group, said: “Biocon opened FY26 with a strong performance, driven by continued gains in Biosimilars and CRDMO, and a steady showing in Generics. Operating Revenue rose 15% YoY to Rs 3,942 crore, with EBITDA up 19% on a like-for-like basis, demonstrating operating leverage and the robustness of our businesses. The recent QIP has strengthened our balance sheet and enables us to increase our ownership in Biocon Biologics by facilitating the exit of structured equity investors, aligning capital structure with long-term strategic priorities. Key developments this quarter include the launch of Yesafili™ in Canada, our tenth biosimilar globally, and USFDA approval for Insulin Aspart, our second interchangeable biosimilar Insulin, further deepening our presence in the U.S. insulin market. With execution momentum across all businesses and expanded capacity through acquisitions in the U.S. by Syngene and Biocon Generics, we are well-positioned to drive long-term value creation in FY26 and beyond.” Siddharth Mittal, CEO & Managing Director, Biocon, said: “The generics business’ performance in the first quarter was in line with expectations, delivering a 6% revenue growth over the previous year. Growth in the quarter was primarily driven by revenues from recent drug product launches, including Liraglutide in the E.U., and Dasatinib and Lenalidomide in the U.S., supported by higher volumes in our API business. The sequential financial performance reflects the one-time positive impact of Lenalidomide launch quantities in Q4FY25. The capitalization of new manufacturing facilities in the previous fiscal impacted margins.We remain focused on launching new products, including the commercialization of Liraglutide across key strategic markets.” Shreehas Tambe, CEO & Managing Director, Biocon Biologics, said: Biocon Biologics started FY26 on a strong footing, delivering 18% year-on-year revenue growth, driven by robust demand across key markets. EBITDA rose 36% Y-o-Y on a like-to-like basis to Rs 645 crore, with a 300 bps sequential margin improvement, driven by improved operating leverage. The U.S. FDA approval of Kirsty™ (bAspart) builds on the strong foundation established with Semglee® (bInsulin Glargine), enabling us to offer patients the full range of affordable short and long-acting insulin therapies. With regulatory approvals for our bDenosumab products — Vevzuo® and Efraxy® — in Europe and the UK, Biocon Biologics now has 12 approved biosimilar molecules globally. The launch of Yesafili® (bAflibercept) in Canada marked our entry into ophthalmology and the successful commercialization of our 10th biosimilar globally. As we enter the ‘Accelerate’ phase, we are confident in our ability to scale, deepen market presence, and deliver sustained growth.” Peter Bains, CEO & Managing Director, Syngene International, said: “We delivered a strong first-quarter performance in line with expectations, with revenue from operations growing 11% year-on-year to Rs 875 crore and EBITDA at Rs 224 crore, reporting a growth of 19%. Growth was driven by continued momentum in Research Services, as pilot programs transitioned into long-term contracts. In Biologics manufacturing, operations have commenced at our Unit III facility in Bengaluru, and preparations are advancing for the Bayview facility in the U.S., scheduled to launch later this year. With a positive first quarter start and strategic investments in scientific capabilities, we remain confident in our ability to deliver on our guidance for the year.” Result PDF